Comparative Pharmacology
Head-to-head clinical analysis: TZ 3 versus ZUSDURI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TZ 3 versus ZUSDURI.
TZ-3 vs ZUSDURI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
ZUSDURI is a small molecule inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), reducing signaling of pro-inflammatory cytokines.
100 mg orally twice daily
200 mg orally once daily, with or without food.
None Documented
None Documented
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
The terminal elimination half-life is approximately 12–15 hours in healthy adults, supporting twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged up to 24 hours, requiring dose adjustment.
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
ZUSDURI is primarily eliminated via hepatic metabolism with subsequent biliary excretion. Approximately 30% of the dose is excreted unchanged in feces, and less than 5% is recovered unchanged in urine. The major metabolites are excreted in bile and eliminated in feces.
Category C
Category C
Unknown
Unknown